
## Kiron M Das

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4559696/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of a U.S. National Cohort to Determine Utilization in Colectomy Rates for Ulcerative Colitis Among Ethnicities. Inflammatory Bowel Diseases, 2022, 28, 54-61.	0.9	3
2	Recurring Translocations in Barrett's Esophageal Adenocarcinoma. Frontiers in Genetics, 2021, 12, 674741.	1.1	3
3	Gene Expression in Barrett's Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma. Cancers, 2021, 13, 5971.	1.7	2
4	Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. Scientific Reports, 2019, 9, 10526.	1.6	9
5	DNA methylation silencing of microRNA gene methylator in the precancerous background mucosa with and without gastric cancer: Analysis of the effects of H. pylori eradication and long-term aspirin use. Scientific Reports, 2019, 9, 12559.	1.6	9
6	Tu1841 – Comparative Analysis of Blood and Mucosal Mir-206 in Ulcerative Colitis Patients Treated with 5-Aminosalicylic Acid (5-ASA). Gastroenterology, 2019, 156, S-1145.	0.6	0
7	Tu1160 – Gene Expression Signature of the "Point of No Return―in Barrett's Epithelial Carcinogenesis. Gastroenterology, 2019, 156, S-967.	0.6	0
8	Sa2015 – 5-Aminosalicylic Acid Inhibits Xenobiotic Metabolism in Patients with Ulcerative Colitis: A Novel Pathway for Chemoprevention. Gastroenterology, 2019, 156, S-472-S-473.	0.6	0
9	miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 78-84.	0.9	9
10	Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Digestive Diseases and Sciences, 2019, 64, 740-750.	1.1	19
11	Long-term effects of H. pylori eradication on epigenetic alterations related to gastric carcinogenesis. Scientific Reports, 2018, 8, 14369.	1.6	26
12	19 - In vitro Studies of HTERT Immortalized Normal Esophageal Squamous Epithelial Cells show Progressive Morphological and Molecular Characteristics of Inflammation:Metaplasia: Neoplasia Sequence. Gastroenterology, 2018, 154, S-7.	0.6	0
13	Barrett's metaplasia develops from cellular reprograming of esophageal squamous epithelium due to gastroesophageal reflux. American Journal of Physiology - Renal Physiology, 2017, 312, G615-G622.	1.6	28
14	Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer. Scientific Reports, 2017, 7, 13384.	1.6	6
15	Acid and Bile Induced TGFB1 and NOTCH1 Regulates Epithelial Mesenchymal Transition in Barrett's Carcinogenesis. Gastroenterology, 2017, 152, S238-S239.	0.6	0
16	In Non-Neoplastic Barrett's Epithelial Cells, Acid and Bile Salts Induce Epithelial Mesenchymal Transition (EMT) through a Hif-Mediated Reduction in Microrna-200a and -200b Expression. Gastroenterology, 2017, 152, S661.	0.6	0
17	Effect of Benzo[A]Pyrene Along with Acid and Bile is Highly Carcinogenic as Shown in Thein-Vitro Barrett's Esophagus Carcinogenesis (BEC) Model. Gastroenterology, 2017, 152, S834-S835.	0.6	0
18	Curcumin, a Nutraceutical, Prevents Acid and Bile Induced Colonic Phenotype of Metaplasia in Bar-T Cells. Gastroenterology, 2017, 152, S836.	0.6	0

#	Article	IF	CITATIONS
19	Novel Recurring Fusions: Predictive Markers of Esophageal Adenocarcinoma. Gastroenterology, 2017, 152, S1029.	0.6	0
20	Su2052 NOTCH1 Is Overexpressed in Barrett's Epithelial Neoplasia and Can Be Inhibited by Curcumin. Gastroenterology, 2016, 150, S622.	0.6	0
21	Tu2055 BMP Pathway Inhibitors May Prevent Neoplastic Progression of Barrett's Epithelium. Gastroenterology, 2016, 150, S1011-S1012.	0.6	0
22	Su2061 Nano-Curcumin Potentiates the Anti-Neoplastic Effects of Mesalamine in Colorectal Cancer. Gastroenterology, 2016, 150, S624.	0.6	0
23	Localization of specialized intestinal metaplasia and the molecular alterations in Barrett esophagus in a Japanese population: an analysis of biopsy samples based on the "Seattle―biopsy protocol. Human Pathology, 2016, 51, 32-40.	1.1	7
24	Sa1957 Nano-Curcumin Inhibits Neoplastic Process in the Barrett's Epithelial Carcinogenesis Model. Gastroenterology, 2015, 148, S-367.	0.6	0
25	Sa1915 Chromosome Translocation T(2,10,16) Marks †Point of No-Return' in Barrett's Epithelium Carcinogenesis, In-Vitro Model. Gastroenterology, 2015, 148, S-354.	0.6	0
26	Sa1886 Esophageal Squamous Cells Exposed Repeatedly to Acid and Bile Salts In Vitro Exhibit Columnar Differentiation With Features of Barrett's Metaplasia. Gastroenterology, 2015, 148, S-346-S-347.	0.6	0
27	544 In Non-Neoplastic Barrett's Epithelial Cells, Acid and Bile Salts Activate VEGF Signaling to Induce Epithelial Mesenchymal Transition Through ZEB2, a Transcriptional Repressor of E-Cadherin. Gastroenterology, 2015, 148, S-109.	0.6	0
28	Sa1960 Carcinogenesis-Genes Identified in Colon Tissue As Possible Targets for Chemo Preventive Effect of Mesalamine in Patients With Chronic Ulcerative Colitis. Gastroenterology, 2014, 146, S-340.	0.6	0
29	Tu1667 Genomic Changes Correlate With Transformed Phenotype in a Dynamic in-Vitro Model of Barrett's Carcinogenesis. Gastroenterology, 2014, 146, S-813-S-814.	0.6	0
30	Sa1954 Benzo[a]Pyrene-Induced CYP 1A1/1B1 Genes May Promote Development of Esophageal Adenocarcinoma While Curcumin Attenuates Such Induction. Gastroenterology, 2014, 146, S-338.	0.6	0
31	930 Acid and Bile Salts Induce Features of Epithelial Mesenchymal Transition in Non-Neoplastic Barrett's Epithelial Cells Through Increased VEGFSignaling. Gastroenterology, 2014, 146, S-160.	0.6	0
32	Mo1903 Molecular Effect of Acid and Bile Suppression on Progression of Be to Neoplasia. Gastroenterology, 2013, 144, S-689.	0.6	0
33	Mo1938 Differential Response of Normal Esophageal Squamous Cells to Acid and Bile Salt-Induced Injury May Predispose to Barrett's Metaplasia. Gastroenterology, 2013, 144, S-700.	0.6	0
34	Mo1935 Exposure to Acid and Bile Salts Induces Features of Epithelial Mesenchymal Transition in Non-Neoplastic Barrett's Epithelial Cells: A Potential Mechanism for Reflux-Induced Remodeling and Carcinogenesis in Barrett's Esophagus. Gastroenterology, 2013, 144, S-699.	0.6	0
35	Barrett's esophagus: cancer and molecular biology. Annals of the New York Academy of Sciences, 2013, 1300, 296-314.	1.8	24
36	High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic <i>inâ€vitro</i> acid and bile exposure in barrett's epithelium cells. Genes Chromosomes and Cancer, 2013, 52, 1123-1132.	1.5	14

#	Article	IF	CITATIONS
37	Mo1946 Progressive Increase in Proliferation, Reduced Apoptosis, and Development of Serum Dependence in Neoplastic Cells of the Barrett's Epithelium Carcinogenesis Model. Gastroenterology, 2013, 144, S-701-S-702.	0.6	0
38	Mo1163 Carcinogenic Effects of Benzo[a]Pyrene (Cyp 450 Activation) on HET-1A and Bar-T Cell Line Could Be Reversed by Curcumin. Gastroenterology, 2013, 144, S-595-S-596.	0.6	1
39	Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma. Annals of the New York Academy of Sciences, 2013, 1300, 187-199.	1.8	25
40	Su1179 Acid Suppression Can Impede Progression of Barrett's Epithelium to Dysplasia. Gastroenterology, 2012, 142, S-444.	0.6	0
41	Su1178 High Resolution Integrative Analysis Reveals Widespread Genetic and Epigenetic Alterations in Barrett's Epithelial Cells Exposed to Acid and Bile. Gastroenterology, 2012, 142, S-444.	0.6	1
42	Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium. Molecular Cytogenetics, 2012, 5, 43.	0.4	18
43	Continued Mesalamine Exposure is Required for Sustained Anti-Inflammatory and Chemoprevention Effects: Molecular Evidence Using an in-Vitro Model. Gastroenterology, 2011, 140, S-401.	0.6	0
44	Aberrant, DNA Damage-Response May Contribute in the Carcinogenesis Process in Barrett's Epithelium. Gastroenterology, 2011, 140, S-667.	0.6	0
45	TC22, a Novel Colorectal Cancer Biomarker Remains Continuously Suppressed Upon Repeated Mesalamine Exposure to Colorectal Cancer Cells. Gastroenterology, 2011, 140, S-344.	0.6	0
46	Cellular Phenotypic Changes With Long-Term Acid and Bile Exposure to a Barrett's Epithelial Cell Line. Gastroenterology, 2011, 140, S-222.	0.6	0
47	Barrett's esophagus: genetic and cell changes. Annals of the New York Academy of Sciences, 2011, 1232, 18-35.	1.8	6
48	Barrett's esophagus: histology and immunohistology. Annals of the New York Academy of Sciences, 2011, 1232, 76-92.	1.8	7
49	Transformation of benign Barrett's epithelium by repeated acid and bile exposure over 65 weeks: A novel <i>in vitro</i> model. International Journal of Cancer, 2011, 128, 274-282.	2.3	39
50	Inducing and Maintaining Remission in Ulcerative Colitis. Journal of Clinical Gastroenterology, 2010, 44, 531-535.	1.1	13
51	S1962 Tropomyosin Isoform, TC22, a Novel Biomarker Associated With Neoplasia and Carcinoma. Gastroenterology, 2010, 138, S-290.	0.6	0
52	S1058 Modulation of Cell Cycle Pathways in an in-Vitro Chronic Acid Plus Bile Exposure Model of Barrett's Epithelium. Gastroenterology, 2010, 138, S-169.	0.6	0
53	S1066 Increase Oncogenecity of Bar-T Cells With Continued Exposure to Acid Plus Bile Beyond 56 Weeks. Gastroenterology, 2010, 138, S-171.	0.6	0
54	Antibody to Tropomyosin Isoform 5 and Complement Induce the Lysis of Colonocytes in Ulcerative Colitis. American Journal of Gastroenterology, 2009, 104, 2996-3003.	0.2	16

#	Article	IF	CITATIONS
55	Mesalamine Suppresses the Expression of TC22, a Novel Tropomyosin Isoform Associated with Colonic Neoplasia. Molecular Pharmacology, 2009, 76, 183-191.	1.0	12
56	ls IBD an autoimmune disorder?. Inflammatory Bowel Diseases, 2008, 14, S97-S101.	0.9	15
57	Repeated exposure to acid and bile selectively induces colonic phenotype expression in a heterogeneous Barrett's epithelial cell line. Laboratory Investigation, 2008, 88, 643-651.	1.7	34
58	899 Transformation of Benign Barrett's Epithelial Cells By Repeated Acid and Bile Exposure Over 22-65 Weeks: An in-Vitro Model of Metaplasia to Neoplasia By Environmental Factors. Gastroenterology, 2008, 134, A-129.	0.6	0
59	W1102 Mesalamine Modulates Several Genes Related to Carcinogenesis, Inflammation, and Cell Cycle Pathways. Gastroenterology, 2008, 134, A-633.	0.6	0
60	M1984 Cellular Phenotypes in Adenocarcinoma of the Esophagus. Gastroenterology, 2008, 134, A-445.	0.6	0
61	T1234 Autoimmunity in Ulcerative Colitis: TNF- $\hat{I}\pm$ and Bacterial Lipopolysaccharide Induce Expression of the Autoantigen Human Tropomyosin Isoform 5. Gastroenterology, 2008, 134, A-512.	0.6	0
62	Tropomyosins in Human Diseases: Ulcerative Colitis. Advances in Experimental Medicine and Biology, 2008, 644, 158-167.	0.8	12
63	An In-Vitro Model of Barrett's Epithelium (BE). American Journal of Gastroenterology, 2006, 101, S62.	0.2	0
64	Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, S290-S294.	1.4	7
65	Isolation and sequencing of a novel tropomyosin isoform preferentially associated with colon cancer. Gastroenterology, 2002, 123, 152-162.	0.6	36
66	Autoimmunity in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology & Hepatology, 1993, 7, 102-109.	1.8	5